Upgrade to SI Premium - Free Trial

Oppenheimer Starts Teva Pharma (TEVA) at Outperform

September 23, 2026 6:12 AM
Oppenheimer analyst Les Sulewski initiates coverage on Teva Pharma (NYSE: TEVA) with a Outperform rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Hot Comments Hot New Coverage New Coverage